Road to a Cure - Drug Resistance
In the seventh episode in our Road to a Cure series, the OMBCL team intrviews Dr. Sarat Chandarlapaty, a leading Physician Scientist in Human Oncology & Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center. We will explore key concepts regarding drug resistance, clinical trials, and the possibility of a cure. Dr. Chandarlapaty breaks down complex concepts into smaller questions to solve the problems related to cancer. The goal of his research is to investigate the mechanisms and consequences of activation of growth factors and hormonal signaling pathways in breast cancer and to translate those findings toward the development of more effective and durable treatments for disease. A major focus of his lab is to characterize the significance of alterations present in breast tumors that have progressed on targeted therapy. This involves studies designed to understand the molecular mechanisms underlying resistance and to identify new molecular targets that may inform novel therapeutic approaches. This has helped to elucidate both immediate and delayed adaptations that promote resistance to standard treatments.
Estrogen Receptor and Growth Factor Resistance
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
PI3Kinase Inhibitor
Targeting the PI3-kinase pathway in triple-negative breast cancer
PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
Liquid Biopsy
Aurora Project:
AURORA US is part of a larger initiative funded by the Breast Cancer Research Foundation (BCRF) to find solutions to breast cancer metastasis.
Funding of Research for Metastatic Breast Cancer:
Meet the Guest of this Episode
Laboratory Head -
Human Oncology & Pathogenesis Program (HOPP)
Memorial Sloan Kettering Cancer Center
Member, Scientific Advisory Board -
Breast Cancer Research Foundation
Major Funding Recipient
the Cancer Couch Foundation
